<DOC>
	<DOCNO>NCT01470469</DOCNO>
	<brief_summary>This study evaluate safety tolerability SPD503 subject age 6-17 year GAD , SAD , SoP base treatment emergent adverse event ( TEAEs ) , vital sign ECGs .</brief_summary>
	<brief_title>SPD503 Subjects Aged 6-17 Years With Generalized Anxiety Disorder ( GAD ) , Separation Anxiety Disorder ( SAD ) , Social Phobia ( SoP )</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Phobic Disorders</mesh_term>
	<mesh_term>Anxiety , Separation</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Guanfacine</mesh_term>
	<criteria>1 . Outpatient subject age 617 year inclusive time consent/assent ( Screening Visit [ Visit 1 ] ) . 2 . Subject 's parent legally authorize representative ( LAR ) must provide signature informed consent , must documentation assent subject indicate subject aware investigational nature study require procedure accordance International Conference Harmonisation ( ICH ) Good Clinical Practice ( GCP ) Guidance E6 ( 1996 ) applicable regulation complete studyrelated procedure ( Screening Visit [ Visit 1 ] ) . 3 . Subject meet Diagnostic Statistical Manual Mental Disorders Fourth Edition , Text Revision ( DSMIVTR ) criteria Primary Diagnosis 1 combination follow ; GAD , SAD SoP ( 300.02 , 309.21 300.23 ) , base detailed psychiatric evaluation screen include completion Anxiety Disorders Interview Schedule DSMIV Child Version ( ADISC ) . 4 . Subject score &gt; /= 4 Clinician Severity Rating Scale Principal Diagnosis ADISC CSR ) Screening Visit ( Visit 1 ) Baseline Visit ( Visit 2 ) . 5 . Subject function ageappropriate level intellectually , determine Investigator . 6 . Subject parent/LAR understand , able , willing , likely fully comply study procedure restriction define protocol , opinion Investigator . 7 . Subject able swallow intact tablet . 8 . Subjects females childbearing potential ( FOCP ) , define &gt; /= 9 year age &lt; 9 year age postmenarchal , must negative serum beta Human Chorionic Gonadotropin ( HCG ) pregnancy test Screening Visit ( Visit 1 ) negative urine pregnancy test Baseline Visit ( Visit 2 ) Week 12 ( Visit 11/ET ) . Females childbearing potential must abstain sexual activity could result pregnancy agree use acceptable method contraception . 1 . Subject current comorbid psychiatric diagnosis major depressive disorder , bipolar illness , psychosis , pervasive development disorder Asperger 's Syndrome , attention deficit hyperactivity disorder , eat disorder , substance abuse disorder . 2 . Subject ADISC CSR score Axis I disorder great ADISC CSR score Principal Diagnosis GAD , SAD , SoP . 3 . Subject condition illness , opinion Investigator , represent inappropriate risk subject and/or could confound interpretation study . 4 . Within 14 day prior Baseline Visit subject receive evidencebased psychosocial intervention intend reduce anxiety symptom i.e . Individual Cognitive Behavioral Therapy , Group Cognitive Behavioral Therapy , Social Effectiveness Training . 5 . Subject start change type intensity non evidencebased psychosocial intervention intend reduce anxiety symptom within 6 week prior Baseline Visit ( Visit 2 ) . 6 . Subject known history presence structural cardiac abnormality , serious heart rhythm abnormality , syncope , cardiac conduction problem ( e.g. , clinically significant heart block ) , exerciserelated cardiac event include syncope pre syncope , clinically significant bradycardia . 7 . Subject orthostatic hypotension know history control uncontrolled hypertension . 8 . Subject blood pressure measurement 95th percentile age , sex , height . 9 . Subject history seizure disorder single childhood febrile seizure occur age 3 year . 10 . Subject currently consider risk suicide opinion Investigator , previously make suicide attempt , currently demonstrate active suicidal ideation . Subjects intermittent passive suicidal ideation necessarily exclude base assessment Investigator . 11 . Subject unable limit caffeine intake 2 serving per day throughout participation study begin time informed consent/assent . 12 . Subject history alcohol substance abuse dependence , define DSMIV within last 6 month . 13 . Clinically important abnormality drug alcohol screen Screening Visit ( Visit 1 ) Baseline Visit ( Visit 2 ) . 14 . History failure respond 2 adequate trial ( consist appropriate dose adequate duration therapy ) SSRI one trial cognitive behavioral therapy treatment GAD , SAD , SoP . 15 . Subject well control anxiolytic pharmacologic nonpharmacologic therapy acceptable tolerability . 16 . Subject currently use prohibit medication medication , include herbal supplement identify anxiolytic anxiogenic effect , affect BP heart rate CNS effect violation protocolspecified washout criterion Baseline Visit ( Visit 2 ) . 17 . Subject currently use valproic acid drug know inhibit induce CYP3A4/5 violation protocolspecified washout criterion Baseline Visit ( Visit 2 ) . 18 . Use another investigational medicinal product participation clinical study within 30 day prior Baseline Visit ( Visit 2 ) . 19 . Subject significantly overweight base Center Disease Control Prevention body mass index ( BMI ) forage sex specific chart Screening Visit ( Visit 1 ) . Significantly overweight define BMI &gt; 95th percentile study . 20 . Subject know suspected allergy , hypersensitivity , clinically significant intolerance guanfacine hydrochloride component find SPD503 . 21 . Subject female pregnant currently lactate . 22 . Subject fail screen previously enrol study . 23 . Subject another member household currently participate study .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>